Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Top Cited Papers
- 11 May 2015
- journal article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 523 (7559), 231-235
- https://doi.org/10.1038/nature14404
Abstract
Melanoma treatment is being revolutionized by the development of effective immunotherapeutic approaches. These strategies include blockade of immune-inhibitory receptors on activated T cells; for example, using monoclonal antibodies against CTLA-4, PD-1, and PD-L1 (refs 3-5). However, only a subset of patients responds to these treatments, and data suggest that therapeutic benefit is preferentially achieved in patients with a pre-existing T-cell response against their tumour, as evidenced by a baseline CD8(+) T-cell infiltration within the tumour microenvironment. Understanding the molecular mechanisms that underlie the presence or absence of a spontaneous anti-tumour T-cell response in subsets of cases, therefore, should enable the development of therapeutic solutions for patients lacking a T-cell infiltrate. Here we identify a melanoma-cell-intrinsic oncogenic pathway that contributes to a lack of T-cell infiltration in melanoma. Molecular analysis of human metastatic melanoma samples revealed a correlation between activation of the WNT/β-catenin signalling pathway and absence of a T-cell gene expression signature. Using autochthonous mouse melanoma models we identified the mechanism by which tumour-intrinsic active β-catenin signalling results in T-cell exclusion and resistance to anti-PD-L1/anti-CTLA-4 monoclonal antibody therapy. Specific oncogenic signals, therefore, can mediate cancer immune evasion and resistance to immunotherapies, pointing to new candidate targets for immune potentiation.Keywords
This publication has 44 references indexed in Scilit:
- An integrated map of genetic variation from 1,092 human genomesNature, 2012
- β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient MelanomasCancer Cell, 2011
- Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cellsThe Journal of Experimental Medicine, 2011
- N-myc Downstream-regulated Gene 2, a Novel Estrogen-targeted Gene, Is Involved in the Regulation of Na+/K+-ATPaseOnline Journal of Public Health Informatics, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigensThe Journal of Experimental Medicine, 2010
- ConsensusClusterPlus: a class discovery tool with confidence assessments and item trackingBioinformatics, 2010
- BrafV600E cooperates with Pten loss to induce metastatic melanomaNature Genetics, 2009
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in miceCurrent Biology, 1998